Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,346.00
Bid: 12,376.00
Ask: 12,380.00
Change: 156.00 (1.28%)
Spread: 4.00 (0.032%)
Open: 12,304.00
High: 12,380.00
Low: 12,088.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

More to come as bear capitulation drives recent risk rally

Mon, 19th Jun 2023 10:48

STOXX 600 down 0.5%

*

Major indices in the red

*

U.S. markets closed for Juneteenth holiday

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

MORE TO COME AS BEAR CAPITULATION DRIVES RECENT RISK RALLY (0948 GMT)

Stock markets are taking a breather on Monday after a rally which has seen the DAX close at a record high on Friday, the Nasdaq surge almost 38% year-to-date and the S&P 500 enter a technical bull market.

Ben Laidler, global markets strategist at eToro, says positive fundamentals have driven the rally but poor investor sentiment has also been important.

"We are now in a positive ‘pain trade’, as previously bearish investors capitulate and chase stocks higher," Laidler writes.

"Poor sentiment has had two benefits, protecting on the downside and is now magnifying the upside."

Laidler says this "bear capitulation" can be powerful and last for a while before sentiment becomes too bullish and the dynamic reverses.

Meanwhile, Jefferies chief financial economist Europe Mohit Kumar says they are retaining their small long position in risky assets amid the recent buoyant mood.

"There is little in terms of data between now and the U.S. payrolls which would dent the recent optimism," Kumar says.

"We still struggle to see significant upside from current levels, but believe that the path of least resistance is for modestly higher risky assets."

(Samuel Indyk)

CAUTIOUS START FOR EUROPE (0811 GMT)

European equity markets are taking a breather on Monday after a strong performance last week that saw Germany's DAX close at a record high and broader European shares notch their biggest weekly gain in two months.

The pan-European benchmark STOXX 600 index is down around 0.6%, while the DAX , CAC 40 and FTSE 100 are down 0.3%-0.6%.

"Investors are lacking Monday motivation today, as caution returns amid worries about global growth," says Susannah Streeter, head of money and markets, Hargreaves Lansdown.

"European indices have opened lower ... as investors mull what's ahead for the path of interest rates, given the stubbornness of inflation, while concerns persist about China's recovery losing steam."

Shares in Franco-German lab supplies maker Sartorius are down around 13% after the company cut its margin and sales forecast.

Aerospace and Defence stocks are a rare bright spot, as attention falls on Paris, where the world's largest aviation trade show is kicking off, with airlines going into the event with growing demand expectations.

Here's your opening snapshot:

(Samuel Indyk)

MONDAY BLUES FOR EUROPEAN FUTURES (0635 GMT)

European equity futures are struggling on Monday, consolidating after major indices clocked their biggest weekly gain in two months last week.

Euro STOXX 50 futures are down 0.6%. Futures on Germany's DAX are also losing 0.6% after the index closed at a

record high

on Friday.

With a U.S. market holiday and a lack of major data releases in Europe, focus is falling on geopolitics as U.S. Secretary of State Antony Blinken wraps up his

trip to China

, where a meeting with Chinese President Xi Jinping might be in the offing.

In company news, AstraZeneca will be in focus after the Financial Times reported the drugmaker is drafting a plan to

spin off its China business.

Attention will also be on aerospace and defence names, as the week-long Paris Airshow kicks off.

(Samuel Indyk)

READY FOR MORE RATE HIKES, AND ONE CUT (0554 GMT)

It's been predictably subdued in Asia as a U.S. holiday provides a convenient excuse for stocks to consolidate recent hefty gains before a bevy of central bank meetings this week. Most indices are down, with the Nikkei off modestly having climbed 22% over a 10-week streak to hit 33-year highs.

S&P 500 futures were also flat having risen for five weeks in a row, while the NASDAQ has notched eight weeks of gains. Those rallies are narrowly based, though, with just nine large-cap stocks making up 30% of the S&P 500. It's hard to call the index a "diversified" investment any more.

Markets are watching U.S. Secretary of State Antony Blinken's visit to Beijing, though you know expectations are low when it's newsworthy that a Chinese diplomat deigned to shake his hand.

Among currencies, the yen downtrend remains alive and well as the euro and dollar both make new highs, albeit by just a few ticks. Further losses look likely unless and until the Bank of Japan takes another step toward tightening, which many Western analysts see as possible in July. Governor Kazuo Ueda, however, seemed to set a high bar for a move last week by saying his outlook for inflation would have to shift "sharply" to justify a move.

The coming week is also jammed with central bank action, led by China on Tuesday where prime loan rates are expected to be cut by 10 basis points. That might be pushing on string given mortgage rates have already fallen markedly and lower rates only eat into the return on household savings. Markets are really hanging on for more fiscal stimulus to revive growth, as it has so often in the past.

Federal Reserve Chair Jerome Powell appears before lawmakers on Wednesday and Thursday and may again try to convince markets that two more quarter-point rate hikes are really, honestly, cross-my-heart likely.

Futures seem unimpressed with just 21 basis points of tightening priced in by September, though one final hike in July is rated as a decent 70% chance.

In contrast, markets are baying for the Bank of England to hike when it meets on Thursday, the only question being by 25 or 50 basis points. Futures lean toward the smaller move to 4.75% but also have rates rising to at least 5.75% given stubborn inflation and surging wages.

Gilt yields have already hit 15-year highs, causing havoc in the UK mortgage market and lifting the government's already astronomical borrowing costs.

Rate hikes are also expected in Norway and Switzerland this week, perhaps by 50 basis points, though that will likely pale in comparison to Turkey's central bank as some analysts see rates rising from the current 8% to as much as 25%.

Key developments that could influence markets on Monday:

- ECB board member Isabel Schnabel, ECB Vice President Luis de Guindos and ECB chief economist Philip Lane are all speaking

- U.S. stock and bond markets are closed, while the NAHB housing market index for June is due

(Wayne Cole)

More News
Today 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
Today 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.